MX2016003979A - Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica. - Google Patents
Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica.Info
- Publication number
- MX2016003979A MX2016003979A MX2016003979A MX2016003979A MX2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A MX 2016003979 A MX2016003979 A MX 2016003979A
- Authority
- MX
- Mexico
- Prior art keywords
- prophylaxis
- treatment
- lupus erythematosus
- systemic lupus
- nephritis
- Prior art date
Links
- 208000005777 Lupus Nephritis Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 2
- -1 citric acid ester Chemical class 0.000 abstract 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886403P | 2013-10-03 | 2013-10-03 | |
| PCT/US2014/058738 WO2015051067A1 (en) | 2013-10-03 | 2014-10-02 | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016003979A true MX2016003979A (es) | 2016-06-15 |
Family
ID=51842818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003979A MX2016003979A (es) | 2013-10-03 | 2014-10-02 | Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160250238A1 (enExample) |
| EP (1) | EP3052105A1 (enExample) |
| JP (1) | JP2016531886A (enExample) |
| KR (1) | KR20160058886A (enExample) |
| CN (1) | CN105705149A (enExample) |
| BR (1) | BR112016007237A2 (enExample) |
| CA (1) | CA2925935A1 (enExample) |
| EA (1) | EA201690686A1 (enExample) |
| MX (1) | MX2016003979A (enExample) |
| WO (1) | WO2015051067A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112423742B (zh) * | 2018-06-27 | 2024-03-19 | 阿尔杰农制药股份有限公司 | 使用阿克他利预防或治疗肾纤维化或肾脏疾病 |
| CA3174375A1 (en) * | 2020-05-07 | 2021-11-11 | Sukchan Lee | Combination therapy of cycloserine and pentoxifylline for the treatment of depression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| DE60239384D1 (de) | 2001-01-25 | 2011-04-21 | Us Of America Represented By The Secretary Dept Of Health And Human Services | Formulierungen von borsäure-verbindungen |
| EP2527347A1 (en) * | 2007-08-06 | 2012-11-28 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| AU2009260778B2 (en) * | 2008-06-17 | 2014-08-28 | Takeda Pharmaceutical Company Limited | Boronate ester compounds and pharmaceutical compositions thereof |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| TW201103904A (en) | 2009-06-11 | 2011-02-01 | Hoffmann La Roche | Janus kinase inhibitor compounds and methods |
| CA2794334C (en) | 2010-03-31 | 2018-06-12 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| TW201309303A (zh) | 2011-03-03 | 2013-03-01 | Cephalon Inc | 用於治療狼瘡的蛋白酶體抑制劑 |
| WO2012177835A1 (en) * | 2011-06-22 | 2012-12-27 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
-
2014
- 2014-10-02 BR BR112016007237A patent/BR112016007237A2/pt not_active IP Right Cessation
- 2014-10-02 EP EP14790872.7A patent/EP3052105A1/en not_active Withdrawn
- 2014-10-02 US US15/026,417 patent/US20160250238A1/en not_active Abandoned
- 2014-10-02 JP JP2016519782A patent/JP2016531886A/ja active Pending
- 2014-10-02 WO PCT/US2014/058738 patent/WO2015051067A1/en not_active Ceased
- 2014-10-02 EA EA201690686A patent/EA201690686A1/ru unknown
- 2014-10-02 MX MX2016003979A patent/MX2016003979A/es unknown
- 2014-10-02 KR KR1020167010114A patent/KR20160058886A/ko not_active Withdrawn
- 2014-10-02 CN CN201480060987.4A patent/CN105705149A/zh active Pending
- 2014-10-02 CA CA2925935A patent/CA2925935A1/en not_active Abandoned
-
2017
- 2017-12-12 US US15/838,595 patent/US20180099000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015051067A1 (en) | 2015-04-09 |
| EA201690686A1 (ru) | 2016-08-31 |
| JP2016531886A (ja) | 2016-10-13 |
| CN105705149A (zh) | 2016-06-22 |
| US20160250238A1 (en) | 2016-09-01 |
| EP3052105A1 (en) | 2016-08-10 |
| CA2925935A1 (en) | 2015-04-09 |
| US20180099000A1 (en) | 2018-04-12 |
| KR20160058886A (ko) | 2016-05-25 |
| BR112016007237A2 (pt) | 2017-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500286A1 (en) | Use of agonists of formly peptide receptor 2 for treating ocular inflammatory diseases | |
| PH12016500649A1 (en) | Combinations of histone deactylase inhibitors and immunomodulatory drugs | |
| IL245117A0 (en) | Co-crystals of (n - (s-methyl-8-(1((2'-methyl-['4,5-bipyrimidine]-6-yl)amino)propane-2-yl)quinoline-4-carboxamide, Derivatives modified by their deuterium, methods for their preparation, preparations containing them and their uses | |
| MX2021011906A (es) | Composiciones de liberacion retardada de linaclotida. | |
| UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
| NZ702967A (en) | Diclofenac formulations | |
| MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
| UA115811C2 (uk) | Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування | |
| NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
| IN2015DN01023A (enExample) | ||
| MX376029B (es) | Compuestos de isoindol. | |
| PH12013500371A1 (en) | Therapeutic agent for pain | |
| EP4385563A3 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| EP4219534A3 (en) | Methods for treatment of and prophylaxis against inflammatory disorders | |
| MX2016003979A (es) | Metodo para profilaxis o tratamiento de lupus eritematoso sistemico y/o nefritis lupica. | |
| MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| MX2015007862A (es) | Derivado de amida del acido cinamico. | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| MX366118B (es) | Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. | |
| WO2014203074A3 (en) | Use of unacylated ghrelin, fragments and analogs thereof as antioxidant | |
| HK1227698A1 (en) | Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis | |
| MX368640B (es) | Composición farmacéutica para tratar inflamación y dolor. | |
| MX2014014817A (es) | Compuestos para el tratamiento de inflamacion y dolor. | |
| IN2013MU03428A (enExample) | ||
| MX2016002139A (es) | Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo. |